Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arvinas reported Q2 2026 revenue of $249.7 million, a significant increase from $22.4 million in the prior year, driven by the FDA approval of VEPPANU and the associated out-licensing deal with Rigel Pharmaceuticals. The company achieved net income of $169.4 million, or $2.58 per diluted share, compared to a net loss of $(61.2) million in the same period last year.
Key figures
- Eps
- 2.58
- Revenue
- 249700000
- Drug Name
- VEPPANU (vepdegestrant)
- Guidance
- Cash, cash equivalents, and marketable securities sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028.
- Ga expense
- 24000000
- Rd expense
- 52600000
- Cash position
- 567900000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.